Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID Trial Diversity: What Participants In The Vaccine Phase III Studies Look Like

Executive Summary

Although differences in how sponsors have publicly disclosed demographic data for their enrolled trials make cross-study comparisons difficult, in general trial enrollment of Black and Hispanic participants has ranged from 10%-19% and 11%-45%, respectively, with one-quarter to one-third of study subjects falling into older age groups.

You may also be interested in...



Clinical Trial Diversity Campaign Distracting From Health Equity Problems, Califf Says

The FDA commissioner says that improving health disparities would fix the lack of diversity in clinical trials.

OCE ‘Project’ To Help Understand Trial Site Selection, Also May Inform Policy

Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.

Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says

COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel